GSA Capital Partners LLP bought a new stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 22,400 shares of the company’s stock, valued at approximately $400,000.

Several other institutional investors have also added to or reduced their stakes in the company. Argent Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 102.6% during the 3rd quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock valued at $2,167,000 after buying an additional 61,425 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock valued at $5,060,000 after buying an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Amphastar Pharmaceuticals by 17.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after buying an additional 226,271 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Amphastar Pharmaceuticals by 11.6% during the 3rd quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock valued at $2,306,000 after buying an additional 13,439 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Amphastar Pharmaceuticals by 164.7% during the 3rd quarter. SG Americas Securities LLC now owns 16,385 shares of the company’s stock valued at $293,000 after buying an additional 10,195 shares during the last quarter. Institutional investors own 44.14% of the company’s stock.

Amphastar Pharmaceuticals Inc (AMPH) opened at $18.06 on Friday. Amphastar Pharmaceuticals Inc has a one year low of $12.05 and a one year high of $19.95. The stock has a market capitalization of $862.97, a price-to-earnings ratio of 125.13, a P/E/G ratio of 1.32 and a beta of 1.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. During the same period last year, the business posted $0.14 earnings per share. The firm’s revenue for the quarter was down 9.8% on a year-over-year basis. analysts predict that Amphastar Pharmaceuticals Inc will post -0.03 EPS for the current fiscal year.

AMPH has been the subject of several research analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $19.00 target price on shares of Amphastar Pharmaceuticals in a research note on Sunday, September 17th. Needham & Company LLC increased their target price on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, September 27th. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Raymond James Financial cut Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a research note on Thursday, November 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.50.

In related news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $18.73, for a total transaction of $147,255.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO William J. Peters sold 3,026 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $18.56, for a total value of $56,162.56. The disclosure for this sale can be found here. Insiders have sold 92,060 shares of company stock worth $1,716,956 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

WARNING: “GSA Capital Partners LLP Buys Shares of 22,400 Amphastar Pharmaceuticals Inc (AMPH)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/06/gsa-capital-partners-llp-buys-shares-of-22400-amphastar-pharmaceuticals-inc-amph.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Stock Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related stocks with our FREE daily email newsletter.